Wire flash
FinanceGossamer Bio reacquires worldwide rights to seralutinib from Chiesi, announces FDA meeting outcome
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Gossamer Bio, Inc. held a business update call to announce several key developments. The company reported the outcome of its pre-NDA Type B meeting with the FDA, including receipt of official minutes. It also announced the reacquisition of worldwide development and commercial rights to seralutinib from Chiesi. Additionally, stockholders approved proposals related to a convertible note exchange and a reverse stock split. The call featured remarks from CFO/COO Bryan Giraudo, with CEO Faheem Hasnain, Chief Development Officer Caryn Peterson, and Commercial Officer Bob Smith available for Q&A. The company emphasized forward-looking statements regarding its planned NDA submission, potential regulatory review and approval timing, and the anticipated benefits of the rights reacquisition.
Source report
Date: [Not specified in original]
Opening Remarks
Bryan Giraudo Chief Financial Officer & Chief Operating Officer
Thank you, operator, and thank you all for joining us today.
Earlier today, we issued a press release announcing several important updates for Gossamer:
- The outcome of our pre-NDA Type B meeting with the Food and Drug Administration (FDA) and receipt of the official minutes
- The reacquisition of worldwide development and commercial rights to seralutinib from Chiesi
- Stockholder approval of the previously announced proposals related to our convertible note exchange and reverse stock split
The press release is available on the Investors section of our website.
Participants
Joining me today are:
- Faheem Hasnain – Chairman, Co-Founder, and Chief Executive Officer
- Caryn Peterson – Chief Development Officer
- Bob Smith – Commercial Officer (available during Q&A)
Forward-Looking Statements
Before we begin, I would like to remind listeners that today's discussion includes forward-looking statements, including statements regarding:
- Our planned NDA submission
- Potential regulatory review and approval timing
- The development and commercialization of seralutinib
- The anticipated benefits of the rights reacquisition
- Our capital structure
- Our financial position and runway
[Operator Instructions for Q&A]
Source
All Articles on Seeking AlphaNeutral / independent
Part of this Story
Gossamer Bio Announces Seralutinib Rights Reacquisition, FDA Meeting Outcome, and Capital Structure Updates